Patent details

Basic Information

Publication number:

EP1280486

PCT Application Number:

PCT/US/2001/013135

Type:

European Patent Granted for LU

Legal Status:

Expired

Application number:

EP019273184

PCT Publication Number:

WO/2001/080796

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

MINIMIZING ADVERSE EXPERIENCE ASSOCIATED WITH OXYBUTYNIN THERAPY

French Title of Invention:

REDUCTION D'EPISODES INDESIRABLES ASSOCIES A UNE THERAPIE PAR L'OXYBUTYNINE

German Title of Invention:

VERMINDERUNG DER NEBENWIRKUNGEN BEI DER OXYBUTYNIN-THERAPIE

SPC Number:

Dates

Filing date:

24/04/2001

Grant date:

17/11/2010

EP Publication Date:

17/11/2010

PCT Publication Date:

01/11/2001

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

05/02/2003

EP B1 Publication Date:

17/11/2010

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

24/04/2021

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

24/04/2001

 

 

Name:

Watson Pharmaceuticals Inc.

Address:

311 Bonnie Circle, Corona, CA 92880, United States (US)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

12/01/2011

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Inventor

1

Name:

EBERT Charles, D.

Address:

United States (US)

2

Name:

SANDERS Steven, W.

Address:

United States (US)

Priority

Priority Number:

559711

Priority Date:

26/04/2000

Priority Country:

United States (US)

Classification

Main IPC Class:

A61K 31/216;

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

21/10/2020

Last Annual Fee Paid Number:

20

Last Annual Fee Paid Amount:

300 Euro

Payer:

DENNEMEYER & CO

Filing date	Document type	Number of pages